Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK discontinues Beano claim

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline Consumer Healthcare disagrees with the Electronic Retailing Self-Regulation Program's determination that the firm failed to support an exclusivity claim for its Beano supplement, but will qualify the claim in future ads, the firm says. The Council of Better Business Bureaus arm's inquiry was conducted after an anonymous competitor complained about a statement on Beano's Web site. The claim, "The only product available that can help prevent gas," was discontinued during the review, but GSK reserved the right to use the statement in future advertising. It defended its position with literature and noted Beano's biggest competitors, including Gas-X, relieve rather than prevent gas. However, ERSP determined the evidence was insufficient in showing that competing products were "ineffective in preventing gas" and that the statement was therefore inaccurate...

You may also be interested in...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts